Global Angioedema Treatment

Angioedema Treatment Comprehensive Study by Type (Antihistamines, Corticosteroids, Others), Application (Hospitals, Clinics, Research Organizations ), Drugs (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor), Route of Administration (Oral, Injections) Players and Region - Global Market Outlook to 2026

Angioedema Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Angioedema is the rapid edema, or swelling, of the area beneath the skin or mucosa. It is normally an allergic reaction, but it can also be hereditary. The treatment for angioedema depends on the cause, but the most important action is to ensure a free airway. This means that in an emergency, a breathing tube might be placed for safety. An allergic reaction may be treated with epinephrine, which is the drug in an EpiPen. Other medications include antihistamines and corticosteroids. If the cause is hereditary, the patient may receive specialized medications, a concentrate of the C1 inhibitor, the protein they are missing, or fresh frozen plasma.This growth is primarily driven by Increasing treatment options for angioedema.

Globally, a noticeable market trend is evident Advancement in medical technology. Major Players, such as AstraZeneca (United Kingdom), F.Hoffmann-La Roche AG (Switzerland), Valeant Pharmaceuticals International (Canada), GlaxoSmithKline (United Kingdom), AstraZeneca (United Kingdom), Sanofi SA (France) and Merck & Co., Inc. (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Drivers
  • Increasing treatment options for angioedema

Market Trend
  • Advancement in medical technology

Restraints
  • High cost associated with treatment

Opportunities
Pharmaceutical drug manufacturers are increasingly focusing on developing novel therapeutics for hereditary angioedema
Challenges
Unaware in many regions

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Angioedema Treatment Study Sheds Light on
— The Angioedema Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Angioedema Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Angioedema Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Antihistamines
  • Corticosteroids
  • Others
By Application
  • Hospitals
  • Clinics
  • Research Organizations 
By Drugs
  • C1 Esterase Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor

By Route of Administration
  • Oral
  • Injections

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing treatment options for angioedema
    • 3.3. Market Challenges
      • 3.3.1. Unaware in many regions
    • 3.4. Market Trends
      • 3.4.1. Advancement in medical technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Angioedema Treatment, by Type, Application, Drugs, Route of Administration and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Angioedema Treatment (Value)
      • 5.2.1. Global Angioedema Treatment by: Type (Value)
        • 5.2.1.1. Antihistamines
        • 5.2.1.2. Corticosteroids
        • 5.2.1.3. Others
      • 5.2.2. Global Angioedema Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Research Organizations 
      • 5.2.3. Global Angioedema Treatment by: Drugs (Value)
        • 5.2.3.1. C1 Esterase Inhibitor
        • 5.2.3.2. Selective Bradykinin B2 Receptor Antagonist
        • 5.2.3.3. Kallikrein Inhibitor
      • 5.2.4. Global Angioedema Treatment by: Route of Administration (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Injections
      • 5.2.5. Global Angioedema Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Angioedema Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F.Hoffmann-La Roche AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Valeant Pharmaceuticals International (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi SA (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co., Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Angioedema Treatment Sale, by Type, Application, Drugs, Route of Administration and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Angioedema Treatment (Value)
      • 7.2.1. Global Angioedema Treatment by: Type (Value)
        • 7.2.1.1. Antihistamines
        • 7.2.1.2. Corticosteroids
        • 7.2.1.3. Others
      • 7.2.2. Global Angioedema Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Research Organizations 
      • 7.2.3. Global Angioedema Treatment by: Drugs (Value)
        • 7.2.3.1. C1 Esterase Inhibitor
        • 7.2.3.2. Selective Bradykinin B2 Receptor Antagonist
        • 7.2.3.3. Kallikrein Inhibitor
      • 7.2.4. Global Angioedema Treatment by: Route of Administration (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Injections
      • 7.2.5. Global Angioedema Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Angioedema Treatment: by Type(USD Million)
  • Table 2. Angioedema Treatment Antihistamines , by Region USD Million (2015-2020)
  • Table 3. Angioedema Treatment Corticosteroids , by Region USD Million (2015-2020)
  • Table 4. Angioedema Treatment Others , by Region USD Million (2015-2020)
  • Table 5. Angioedema Treatment: by Application(USD Million)
  • Table 6. Angioedema Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 7. Angioedema Treatment Clinics , by Region USD Million (2015-2020)
  • Table 8. Angioedema Treatment Research Organizations  , by Region USD Million (2015-2020)
  • Table 9. Angioedema Treatment: by Drugs(USD Million)
  • Table 10. Angioedema Treatment C1 Esterase Inhibitor , by Region USD Million (2015-2020)
  • Table 11. Angioedema Treatment Selective Bradykinin B2 Receptor Antagonist , by Region USD Million (2015-2020)
  • Table 12. Angioedema Treatment Kallikrein Inhibitor , by Region USD Million (2015-2020)
  • Table 13. Angioedema Treatment: by Route of Administration(USD Million)
  • Table 14. Angioedema Treatment Oral , by Region USD Million (2015-2020)
  • Table 15. Angioedema Treatment Injections , by Region USD Million (2015-2020)
  • Table 16. South America Angioedema Treatment, by Country USD Million (2015-2020)
  • Table 17. South America Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 18. South America Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 19. South America Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 20. South America Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 21. Brazil Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 22. Brazil Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 23. Brazil Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 24. Brazil Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 25. Argentina Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 26. Argentina Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 27. Argentina Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 28. Argentina Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 29. Rest of South America Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 30. Rest of South America Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 31. Rest of South America Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 32. Rest of South America Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 33. Asia Pacific Angioedema Treatment, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 35. Asia Pacific Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 36. Asia Pacific Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 37. Asia Pacific Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 38. China Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 39. China Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 40. China Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 41. China Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 42. Japan Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 43. Japan Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 44. Japan Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 45. Japan Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 46. India Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 47. India Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 48. India Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 49. India Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 50. South Korea Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 51. South Korea Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 52. South Korea Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 53. South Korea Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 54. Taiwan Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 55. Taiwan Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 56. Taiwan Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 57. Taiwan Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 58. Australia Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 59. Australia Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 60. Australia Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 61. Australia Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 66. Europe Angioedema Treatment, by Country USD Million (2015-2020)
  • Table 67. Europe Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 68. Europe Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 69. Europe Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 70. Europe Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 71. Germany Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 72. Germany Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 73. Germany Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 74. Germany Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 75. France Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 76. France Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 77. France Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 78. France Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 79. Italy Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 80. Italy Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 81. Italy Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 82. Italy Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 83. United Kingdom Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 84. United Kingdom Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 85. United Kingdom Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 86. United Kingdom Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 87. Netherlands Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 88. Netherlands Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 89. Netherlands Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 90. Netherlands Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 91. Rest of Europe Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 92. Rest of Europe Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 93. Rest of Europe Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 94. Rest of Europe Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 95. MEA Angioedema Treatment, by Country USD Million (2015-2020)
  • Table 96. MEA Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 97. MEA Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 98. MEA Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 99. MEA Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 100. Middle East Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 101. Middle East Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 102. Middle East Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 103. Middle East Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 104. Africa Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 105. Africa Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 106. Africa Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 107. Africa Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 108. North America Angioedema Treatment, by Country USD Million (2015-2020)
  • Table 109. North America Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 110. North America Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 111. North America Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 112. North America Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 113. United States Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 114. United States Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 115. United States Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 116. United States Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 117. Canada Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 118. Canada Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 119. Canada Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 120. Canada Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 121. Mexico Angioedema Treatment, by Type USD Million (2015-2020)
  • Table 122. Mexico Angioedema Treatment, by Application USD Million (2015-2020)
  • Table 123. Mexico Angioedema Treatment, by Drugs USD Million (2015-2020)
  • Table 124. Mexico Angioedema Treatment, by Route of Administration USD Million (2015-2020)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Angioedema Treatment: by Type(USD Million)
  • Table 133. Angioedema Treatment Antihistamines , by Region USD Million (2021-2026)
  • Table 134. Angioedema Treatment Corticosteroids , by Region USD Million (2021-2026)
  • Table 135. Angioedema Treatment Others , by Region USD Million (2021-2026)
  • Table 136. Angioedema Treatment: by Application(USD Million)
  • Table 137. Angioedema Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 138. Angioedema Treatment Clinics , by Region USD Million (2021-2026)
  • Table 139. Angioedema Treatment Research Organizations  , by Region USD Million (2021-2026)
  • Table 140. Angioedema Treatment: by Drugs(USD Million)
  • Table 141. Angioedema Treatment C1 Esterase Inhibitor , by Region USD Million (2021-2026)
  • Table 142. Angioedema Treatment Selective Bradykinin B2 Receptor Antagonist , by Region USD Million (2021-2026)
  • Table 143. Angioedema Treatment Kallikrein Inhibitor , by Region USD Million (2021-2026)
  • Table 144. Angioedema Treatment: by Route of Administration(USD Million)
  • Table 145. Angioedema Treatment Oral , by Region USD Million (2021-2026)
  • Table 146. Angioedema Treatment Injections , by Region USD Million (2021-2026)
  • Table 147. South America Angioedema Treatment, by Country USD Million (2021-2026)
  • Table 148. South America Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 149. South America Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 150. South America Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 151. South America Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 152. Brazil Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 153. Brazil Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 154. Brazil Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 155. Brazil Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 156. Argentina Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 157. Argentina Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 158. Argentina Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 159. Argentina Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 160. Rest of South America Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 161. Rest of South America Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 162. Rest of South America Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 163. Rest of South America Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 164. Asia Pacific Angioedema Treatment, by Country USD Million (2021-2026)
  • Table 165. Asia Pacific Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 166. Asia Pacific Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 167. Asia Pacific Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 168. Asia Pacific Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 169. China Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 170. China Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 171. China Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 172. China Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 173. Japan Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 174. Japan Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 175. Japan Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 176. Japan Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 177. India Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 178. India Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 179. India Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 180. India Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 181. South Korea Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 182. South Korea Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 183. South Korea Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 184. South Korea Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 185. Taiwan Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 186. Taiwan Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 187. Taiwan Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 188. Taiwan Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 189. Australia Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 190. Australia Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 191. Australia Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 192. Australia Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 193. Rest of Asia-Pacific Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 194. Rest of Asia-Pacific Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 195. Rest of Asia-Pacific Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 196. Rest of Asia-Pacific Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 197. Europe Angioedema Treatment, by Country USD Million (2021-2026)
  • Table 198. Europe Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 199. Europe Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 200. Europe Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 201. Europe Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 202. Germany Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 203. Germany Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 204. Germany Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 205. Germany Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 206. France Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 207. France Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 208. France Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 209. France Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 210. Italy Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 211. Italy Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 212. Italy Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 213. Italy Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 214. United Kingdom Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 215. United Kingdom Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 216. United Kingdom Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 217. United Kingdom Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 218. Netherlands Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 219. Netherlands Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 220. Netherlands Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 221. Netherlands Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 222. Rest of Europe Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 223. Rest of Europe Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 224. Rest of Europe Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 225. Rest of Europe Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 226. MEA Angioedema Treatment, by Country USD Million (2021-2026)
  • Table 227. MEA Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 228. MEA Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 229. MEA Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 230. MEA Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 231. Middle East Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 232. Middle East Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 233. Middle East Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 234. Middle East Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 235. Africa Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 236. Africa Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 237. Africa Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 238. Africa Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 239. North America Angioedema Treatment, by Country USD Million (2021-2026)
  • Table 240. North America Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 241. North America Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 242. North America Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 243. North America Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 244. United States Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 245. United States Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 246. United States Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 247. United States Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 248. Canada Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 249. Canada Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 250. Canada Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 251. Canada Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 252. Mexico Angioedema Treatment, by Type USD Million (2021-2026)
  • Table 253. Mexico Angioedema Treatment, by Application USD Million (2021-2026)
  • Table 254. Mexico Angioedema Treatment, by Drugs USD Million (2021-2026)
  • Table 255. Mexico Angioedema Treatment, by Route of Administration USD Million (2021-2026)
  • Table 256. Research Programs/Design for This Report
  • Table 257. Key Data Information from Secondary Sources
  • Table 258. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Angioedema Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Angioedema Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Angioedema Treatment: by Drugs USD Million (2015-2020)
  • Figure 7. Global Angioedema Treatment: by Route of Administration USD Million (2015-2020)
  • Figure 8. South America Angioedema Treatment Share (%), by Country
  • Figure 9. Asia Pacific Angioedema Treatment Share (%), by Country
  • Figure 10. Europe Angioedema Treatment Share (%), by Country
  • Figure 11. MEA Angioedema Treatment Share (%), by Country
  • Figure 12. North America Angioedema Treatment Share (%), by Country
  • Figure 13. Global Angioedema Treatment share by Players 2020 (%)
  • Figure 14. Global Angioedema Treatment share by Players (Top 3) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 18. F.Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. F.Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 20. Valeant Pharmaceuticals International (Canada) Revenue, Net Income and Gross profit
  • Figure 21. Valeant Pharmaceuticals International (Canada) Revenue: by Geography 2020
  • Figure 22. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 24. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 26. Sanofi SA (France) Revenue, Net Income and Gross profit
  • Figure 27. Sanofi SA (France) Revenue: by Geography 2020
  • Figure 28. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Global Angioedema Treatment: by Type USD Million (2021-2026)
  • Figure 31. Global Angioedema Treatment: by Application USD Million (2021-2026)
  • Figure 32. Global Angioedema Treatment: by Drugs USD Million (2021-2026)
  • Figure 33. Global Angioedema Treatment: by Route of Administration USD Million (2021-2026)
  • Figure 34. South America Angioedema Treatment Share (%), by Country
  • Figure 35. Asia Pacific Angioedema Treatment Share (%), by Country
  • Figure 36. Europe Angioedema Treatment Share (%), by Country
  • Figure 37. MEA Angioedema Treatment Share (%), by Country
  • Figure 38. North America Angioedema Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • F.Hoffmann-La Roche AG (Switzerland)
  • Valeant Pharmaceuticals International (Canada)
  • GlaxoSmithKline (United Kingdom)
  • AstraZeneca (United Kingdom)
  • Sanofi SA (France)
  • Merck & Co., Inc. (United States)
Select User Access Type

Key Highlights of Report


Dec 2021 217 Pages 68 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Angioedema Treatment Quantitative research analysis
Global Angioedema Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Angioedema Treatment Market are AstraZeneca (United Kingdom), F.Hoffmann-La Roche AG (Switzerland), Valeant Pharmaceuticals International (Canada), GlaxoSmithKline (United Kingdom), AstraZeneca (United Kingdom), Sanofi SA (France) and Merck & Co., Inc. (United States) etc.
Angioedema is the rapid edema, or swelling, of the area beneath the skin or mucosa. It is normally an allergic reaction, but it can also be hereditary. The treatment for angioedema depends on the cause, but the most important action is to ensure a free airway. This means that in an emergency, a breathing tube might be placed for safety. An allergic reaction may be treated with epinephrine, which is the drug in an EpiPen. Other medications include antihistamines and corticosteroids. If the cause is hereditary, the patient may receive specialized medications, a concentrate of the C1 inhibitor, the protein they are missing, or fresh frozen plasma.

Know More About Global Angioedema Treatment Report?

Have a Query? Click Here

Other Related Reports

Sodium Chloride Injection Comprehensive Study by Application (Hospitals, Clinics, Other Medical Institutions), Container (Flexible Bag, Plastic Bottles, Glass Bottles), Distribution Channel (Online, ...
$ 3500
Lactulose Concentrate Comprehensive Study by Type (Chemical Synthesis, Enzymatic Method), Application (Pharmaceuticals, Food Industry, Other) Players and Region - Global Market Outlook to 2026
$ 3500
Calcitonin Injection Comprehensive Study by Type (Elcatonin Injection, Salmon Calcitonin Injection), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Regio...
$ 3500
Naltrexone HCl Comprehensive Study by Type (Tablet, Capsule), Application (Alcohol Independence, Opioid Independence, Others), Distribution Channel (Hospital, Pharmacies) Players and Region - Global ...
$ 3500
Chemical Pharmaceutical Comprehensive Study by Type (Oral Pharmaceuticals, Injectable Pharmaceuticals, Topical Pharmaceuticals, Others), Application (Pharmaceutical Industries, Research Organizations...
$ 3450
Travel Vaccines Comprehensive Study by Type (Hepatitis B Vaccines, Hepatitis A Vaccines, Typhoid and paratyphoid fever., Meningococcal Vaccines, Others), Application (Domestic Travel, Outbound Travel...
$ 3450